Molecular genetics and phenomics of RET mutations: Impact on prognosis of MTC

Molecular and Cellular Endocrinology

Volumn 322, Issue 1-2, 2010, Pages 2-7

  Frank Raue, Karin ^a   Rondot, Susanne ^a   Raue, Friedhelm ^a  

^a Endocrine Practice   (Germany)

Author keywords

Genotype phenotype correlation; Medullary thyroid carcinoma; Multiple endocrine neoplasia; RET mutation

Indexed keywords

CALCITONIN; PROTEIN RET;

AUTOSOMAL DOMINANT DISORDER; CANCER SCREENING; CANCER STAGING; CARCINOGENESIS; CLINICAL FEATURE; EARLY DIAGNOSIS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; LINKAGE ANALYSIS; MISSENSE MUTATION; MOLECULAR GENETICS; MULTIPLE ENDOCRINE NEOPLASIA; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2; MUTATIONAL ANALYSIS; NEUROFIBROMATOSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SIPPLE SYNDROME; SOMATIC MUTATION; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY;

CARCINOMA, MEDULLARY; GENETIC ASSOCIATION STUDIES; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B; MUTATION; PHENOTYPE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS;

EID: 77952877804     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2010.01.012     Document Type: Review

References (36)

1. Asai N., Iwashita T., Matsuyama M., Takahashi M. Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol. Cell. Biol. 1995, 15:1613-1619.
2. Bergholm U., Bergstrom R., Ekbom A. Long-term follow-up of patients with medullary carcinoma of the thyroid. Cancer 1997, 79:132-138.
3. Berndt I., Reuter M., Saller B., Frank-Raue K., Groth P., Grussendorf M., Raue F., Ritter M.M., Hoppner W. A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J. Clin. Endocrinol. Metab. 1998, 83:770-774.
4. Brandi M.L., Gagel R.F., Angeli A., Bilezikian J.P., Beck-Peccoz P., Bordi C., Conte-Devolx B., Falchetti A., Gheri R.G., Libroia A., Lips C.J.M., Lombardi G., Mannelli M., Pacini F., Ponder B.A.J., Raue F., Skogseid B., Tamburrano G., Thakker R.V., Thompson N.W., Tomassetti P., Tonelli F., Wells S.A., Marx S.J. Guidelines for diagnosis and therapy of MEN Type 1 and Type 2. J. Clin. Endocrinol. Metab. 2001, 86:5658-5671.
5. Colombo-Benkmann M., Li Z., Riemann B., Hengst K., Herbst H., Keuser R., Groß U., Rondot S., Raue F., Senninger N., Pützer B.M., Frank-Raue K. Characterization of the RET protooncogene transmembrane domain mutation S649L associated with nonaggressive medullary thyroid carcinoma. Eur. J. Endocrinol. 2008, 158:811-816.
6. de Groot J.W., Plukker J.T.M., Wolffenbuttel B.H.R., Wiggers T., Sluiter W.J., Links T.P. Determinants of life expectancy in medullary thyroid cancer: age does not matter. Clin. Endocrinol. 2006, 65:729-736.
7. de Groot J.W., Links T.P., Plukker J.T.M., Lips C., Hofstra M.W. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumours. Endocr. Rev. 2006, 27:535-560.
8. Donis-Keller H., Dou S., Chi D., Carlson K.M., Toshiama K., Lairmore T.G., Howe J.R., Moley J.F., Goodfellow P., Wells S.A. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum. Mol. Genet. 1993, 2:851-856.
9. Elisei R., Romei C., Cosci B., Agate L., Bottici V., Molinaro E., Sculli M., Miccoli P., Basolo F., Grasso L., Pacini F., Pinchera A. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J. Clin. Endocrinol. Metab. 2007, 92:4725-4729.
10. Elisei R., Cosci B., Romei C., Bottici V., Renzini G., Molinaro E., Agate L., Vivaldi A., Faviana P., Basolo F., Miccoli P., Berti P., Pacini F., Pinchera A. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J. Clin. Endocrinol. Metab. 2008, 93:682-687.
11. Eng C., Clayton D., Schuffenecker I., Lenoir G., Cote G., Gagel R.F., van Amstel H.K., Lips C.J., Nishisho I., Takai S.I., Marsh D.J., Robinson B.G., Frank-Raue K., Raue F., Xue F., Noll W.W., Romei C., Pacini F., Fink M., Niederle B., Zedenius J., Nordenskjold M., Komminoth P., Hendy G.N., Gharib H., Thibodeau S.N., Lacroix A., Frilling A., Ponder B.A.J., Mulligan L.M. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 1996, 276:1575-1579.
12. Eng C., Mulligan L.M., Healey C.S., Houghton C., Frilling A., Raue F., Thomas G.A., Ponder B.A. Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. Cancer Res. 1996, 56:2167-2170.
13. Feldmann G.L., Edmonds M.W., Ainsworth P.J., Schuffenecker I., Lenoir G.M., Saxe A.W., Talpos G.B., Robertson J., Petrucelli N., Jackson C.E. Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to RET V804M (GTG-ATG) mutation. Surgery 2000, 128:93-98.
14. Frank-Raue K., Buhr H., Dralle H., Klar E., Senninger N., Weber T., Rondot S., Höppner W., Raue F. Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype. Eur. J. Endocrinol. 2006, 155:229-236.
15. Frank-Raue K., Rondot S., Schulze E., Raue F. Change in the spectrum of RET mutations diagnosed between 1994 and 2006. Clin. Lab. 2007, 53:273-282.
16. Frank-Raue K., Machens A., Scheuba C., Niederle B., Dralle H., Raue F. Difference in the development of medullary thyroid carcinoma among carriers of RET mutations in codon 790 and 791. Clin. Endocrinol. 2008, 69:259-263. The German MEN 2 Study Group.
17. Frank-Raue, K., Döhring, J., Scheumann, G., Rondot, S., Lorenz, A., Schulze, E., Dralle, H., Raue, F., Leidig-Bruckner, G., 2010. New mutations in the RET protooncogene - L881V - associated with medullary thyroid carcinoma and - R770Q - in a patient with mixed medullar/follicular thyroid tumour. Exp. Clin. Endocrinol. Diab., e-pub ahead, doi:10.1055/s-0029-1241851.
18. Hubner R.A., Houlston R.S. Molecular advances in medullary thyroid cancer diagnosis. Clin. Chim. Acta 2006, 370:2-8.
19. Ito S., Iwashita T., Asai N., Murakami H., Iwata Y., Sobue G., Takahashi M. Biological properties of ret with cysteine mutations correlate with multiple endocrine neoplasia Type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype. Cancer Res. 1997, 57:2870-2872.
20. Kebebew E., Ituarte P.H.G., Siperstein A.E., Duh Q.Y., Clark O.H. Medullary thyroid carcinoma, clinical characteristics, treatment, prognostic factors and a comparison of staging systems. Cancer 2000, 88:1139-1148.
21. Kloos R.T., Eng C., Evans D.B., Francis G.L., Gagel R.F., Gharib H., Moley J.F., Pacini F., Ringel M.D., Schlumberger M., Wells S.A. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009, 19:565-612.
22. Kouvaraki M.A., Shapiro S.E., Perrier N.D., Cote G.J., Gagel R.F., Hoff A.O., Sherman S.I., Lee J.E., Evans D.B. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 2005, 15:531-544.
23. Machens A., Niccoli-Sire P., Hoegel J., Frank-Raue K., van Vroonhoven T.J., Roeher H.D., Wahl R., Lamesch P., Raue F., Conte-Devolx B., Dralle H. Early malignant progression of hereditary medullary thyroid cancer. N. Engl. J. Med. 2003, 349:1517-1525. for the European Multiple Endocrine Neoplasia (EUROMEN) Study Group.
24. Machens A., Brauckhoff M., Holzhausen H.J., Thanh P.N., Lehnert H., Dralle H. Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2. J. Clin. Endocrinol. Metab. 2005, 90:3999-4003.
25. Machens A., Hauptmann S., Dralle H. Modification of multiple endocrine neoplasia 2A phenotype by cell membrane proximity of RET mutations in exon 10. Endocr.-Relat. Cancer 2009, 16:171-177.
26. Mulligan L.M., Kwok J.B.J., Healey C.S., Elsdon M.J., Eng C., Gardner E., Love D.R., Mole S.E., Moore J.K., Papi L., Ponder M.A., Telenius H., Tunnacliffe A., Ponder B.A.J. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2a (MEN 2A). Nature 1993, 363:458-469.
27. Punales M.K., Graf H., Gross J.L., Maia A.L. RET codon 634 mutation in multiple endocrine neoplasia type 2: variable clinical features and clinical outcome. J. Clin. Endocrinol. Metab. 2003, 88:2644-2649.
28. Quayle F.J., Fialkowski E.A., Benveniste R., Moley J.F. Pheochromocytoma penetrance varies by RET mutation in MEN 2A. Surgery 2007, 142:800-805.
29. Raue F. German medullary thyroid carcinoma/multiple endocrine neoplasia registry. Langenbeck's Arch. Surg. 1998, 383:334-336.
30. Roman S., Lin R., Sosa J.A. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathological predictors of survival in 1252 cases. Cancer 2006, 107:2134-2142.
31. Schilling T., Burck J., Sinn H.P., Clemens A., Otto H.F., Hoeppner W., Herfarth C., Ziegler R., Schwab M., Raue F. Prognostic value of codon 918 (ATG-OACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. Int. J. Cancer 2001, 95:62-66.
32. Schuffenecker I., Virally-Monod M., Brohet R., Goldgar D., Conte-Devolx B., Leclerc L., Chabre O., Boneu A., Caron J., Houdent C., Modigliani E., Rohmer V., Schlumberger M., Eng C., Guillausseau P.J., Lenoir G.M. Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. J. Clin. Endocrinol. Metab. 1998, 83:487-491. le Groupe d'Etude des Tumeurs a Calcitonine.
33. Skinner M.A., Moley J.A., Dilley W.G., Owzar K., Debenedetti M.K., Wells S.A. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2. N. Engl. J. Med. 2005, 353:1105-1113.
34. Yip L., Cote G.L., Shapiro S.E., Ayers G.D., Herzog C.E., Sellin R.V., Sherman S.I., Gagel R.F., Evans D.B. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch. Surg. 2003, 138:409-416.
35. Zedenius J., Larsson C., Bergholm U., Bovee J., Svensson A., Hallengreen B., Grimelius L., Backdahl M., Weber G., Wallin G. Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas. J. Clin. Endocrinol. Metab. 1995, 80:3088-3090.
36. Zenaty D., Aigrain Y., Peuchmaur M., Philippe-Chomette P., Baumann C., Cornelis F., Hugot J.P., Chevenne D., Barbu V., Guillausseau P.J., Schlumberger M., Carel J.C., Travagli J.P., Leger J. Medullary thyroid carcinoma identified within the first year of life in children with hereditary multiple endocrine neoplasia type 2A (codon 634) and 2B. Eur. J. Endocrinol. 2009, 160:807-813.